{"filing":{"accession_number":"0001171843-26-003617","cik":"0001674632","ticker":"BBNX","company_name":"Beta Bionics, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"f8k_052126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1674632/000117184326003617/f8k_052126.htm"},"events":[{"id":9364,"run_id":8214,"accession_number":"0001171843-26-003617","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Beta Bionics announced an updated commercialization timeline for its lead product candidate, Mint ACE insulin pump, expecting full commercialization by end of Q2 2027 subject to FDA clearance. This material product development milestone affects investor assessment of the company's near-term revenue prospects and regulatory progress.","company_name":"Beta Bionics, Inc.","ticker":"BBNX","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":974,"accession_number":"0001171843-26-003617","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Beta Bionics disclosed updated timeline expectations for commercialization of its lead product candidate, Mint (a patch pump in development), via press release on May 21, 2026. For a development-stage biotech company, material changes to product commercialization timelines are significant to investors assessing the company's path to revenue and capital requirements. This does not fit neatly into the specific event categories (not an earnings release, M\u0026A, impairment, or litigation), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:35:07.310191+00:00","company_name":"","ticker":null,"filing_date":""},{"id":975,"accession_number":"0001171843-26-003617","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Beta Bionics announced an updated commercialization timeline for its Mint ACE insulin pump, expecting full commercialization by end of Q2 2027 subject to FDA clearance. This is a material product development milestone for a medical device company, but does not fit neatly into the standard 8-K taxonomy (not an earnings release, M\u0026A activity, impairment, or other specific event type). The disclosure would affect investor assessment of the company's near-term revenue prospects and regulatory progress, warranting classification as a material event outside the defined categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:35:07.310191+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":974,"accession_number":"0001171843-26-003617","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Beta Bionics disclosed updated timeline expectations for commercialization of its lead product candidate, Mint (a patch pump in development), via press release on May 21, 2026. For a development-stage biotech company, material changes to product commercialization timelines are significant to investors assessing the company's path to revenue and capital requirements. This does not fit neatly into the specific event categories (not an earnings release, M\u0026A, impairment, or litigation), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:35:07.310191+00:00","company_name":"Beta Bionics, Inc.","ticker":"BBNX","filing_date":"2026-05-21"},{"id":975,"accession_number":"0001171843-26-003617","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Beta Bionics announced an updated commercialization timeline for its Mint ACE insulin pump, expecting full commercialization by end of Q2 2027 subject to FDA clearance. This is a material product development milestone for a medical device company, but does not fit neatly into the standard 8-K taxonomy (not an earnings release, M\u0026A activity, impairment, or other specific event type). The disclosure would affect investor assessment of the company's near-term revenue prospects and regulatory progress, warranting classification as a material event outside the defined categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:35:07.310191+00:00","company_name":"Beta Bionics, Inc.","ticker":"BBNX","filing_date":"2026-05-21"}]}